GlassScriptPhysician profile
Okezie Aguoru
NPI 1063677672
$4,024.68
in general payments reported to CMS, 2019-2025
21 companies · $815 in 2025
The $815 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $194 · 2021: $470 · 2022: $722 · 2023: $688 · 2024: $717 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $937.69 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $853.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.63 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $441.55 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $215.62 | 2019-2025 | |
| Lilly USA, LLC | $147.14 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $144.89 | 2022-2023 | |
| Abbott Laboratories | $141.95 | 2022-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $138.51 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $98.68 | 2019-2021 | |
| Curiteva, INC. | $80.78 | 2024 | |
| Dexcom, INC. | $71.65 | 2022-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $66.79 | 2021-2024 | Veozah |
| Mannkind Corporation | $59.40 | 2022 | |
| Calliditas Therapeutics US INC. | $52.04 | 2025 | Tarpeyo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $31.37 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Indivior INC. | $23.94 | 2022 | |
| Amgen INC. | $17.24 | 2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $17.08 | 2022 | |
| Exact Sciences Corporation | $15.30 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.04 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Okezie Aguoru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.